This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- newly diagnosed
- ejection fraction
- ankylosing spondylitis
- chronic kidney disease
- juvenile idiopathic arthritis
- prognostic factors
- peritoneal dialysis
- systemic lupus erythematosus
- ulcerative colitis
- combination therapy
- hidradenitis suppurativa
- smoking cessation